For the millions of adults whose depression has survived multiple rounds of antidepressants and psychotherapy, the therapeutic pipeline has long felt empty. This double-blind, placebo-controlled feasibility trial from an NHS site in England offers one of the most rigorously designed human datasets yet on psilocybin for treatment-resistant major depressive disorder — and its effect sizes are striking enough to demand attention from clinicians and researchers alike.
Sixty participants who had failed at least two antidepressant treatments or one antidepressant plus a course of psychotherapy were randomized 1:1 to receive either a single 25-mg psilocybin dose or placebo, each embedded within a structured psychological support protocol covering preparation, in-session dosing support, and post-session integration. Retention was near-perfect: 59 of 60 participants completed all follow-up assessments. On the Montgomery-Åsberg Depression Rating Scale, the adjusted between-group difference at week three reached -10.41 points (95% CI: -14.86 to -5.95), corresponding to a Cohen's d of -1.70 — an unusually large effect for a single-dose psychiatric intervention. Critically, this separation was maintained at the six-week endpoint. Adverse event counts were modestly higher in the psilocybin arm (164 vs. 123 in placebo), though all were classified as nonserious.
Effect sizes of this magnitude in treatment-resistant populations are rare and should be interpreted carefully. The trial was explicitly designed as a feasibility study — powered for recruitment and retention metrics, not definitive efficacy — meaning these numbers, while compelling, cannot yet be treated as confirmatory. The sample of 60 is small, the follow-up window of six weeks captures none of the longer-term durability questions that matter most clinically, and single-site designs limit generalizability. That said, the NHS public-healthcare context is meaningful: demonstrating operational feasibility within a resource-constrained health system addresses a translational gap that earlier private-clinic trials left open. When placed alongside the Imperial College and COMPASS Pathways phase IIb data, this trial adds important convergent evidence while making the case for a larger confirmatory study — which the authors explicitly endorse. Incremental in design scope, but potentially pivotal in public-health framing.